Stay updated on Alvocidib Biomarker AML Phase 2 Clinical Trial

Sign up to get notified when there's something new on the Alvocidib Biomarker AML Phase 2 Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Alvocidib Biomarker AML Phase 2 Clinical Trial page

  1. Check
    2 days ago
    No Change Detected
  2. Check
    10 days ago
    Change Detected
    Summary
    Revision updated from v3.5.0 to v3.5.2. No visible changes to study data, eligibility criteria, or page navigation.
    Difference
    0.0%
    Check dated 2026-04-16T10:43:51.000Z thumbnail image
  3. Check
    17 days ago
    No Change Detected
  4. Check
    31 days ago
    Change Detected
    Summary
    Revision updated from v3.4.3 to v3.5.0.
    Difference
    0.0%
    Check dated 2026-03-25T20:56:05.000Z thumbnail image
  5. Check
    45 days ago
    Change Detected
    Summary
    Page revision updated from v3.4.2 to v3.4.3.
    Difference
    0.0%
    Check dated 2026-03-11T14:23:32.000Z thumbnail image
  6. Check
    74 days ago
    Change Detected
    Summary
    Added Revision: v3.4.2; removed the lapse-in-funding notice and Revision: v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.3%
    Check dated 2026-02-11T02:01:02.000Z thumbnail image
  7. Check
    81 days ago
    Change Detected
    Summary
    A government funding/status notice was added and the page revision updated to v3.4.1 (replacing v3.4.0).
    Difference
    0.3%
    Check dated 2026-02-03T23:59:52.000Z thumbnail image
  8. Check
    88 days ago
    Change Detected
    Summary
    Added a glossary toggle and minor typography changes (e.g., capitalization and version string) that do not affect study content or navigation. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.2%
    Check dated 2026-01-28T00:16:07.000Z thumbnail image

Stay in the know with updates to Alvocidib Biomarker AML Phase 2 Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Alvocidib Biomarker AML Phase 2 Clinical Trial page.